ALNY vs RARE
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. RARE: Ultragenyx is a biopharmaceutical company dedicated to transforming the lives of patients suffering from rare and ultra-rare genetic diseases through innovative therapeutic development.
Side-by-side fundamentals
| Metric | ALNY | RARE | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $236.01 | $25.83 | |
| Market cap as of 2026-08-25 | $31.6B | $2.5B | |
| P/E as of 2026-08-25 | 37.61 | n/a | |
| PEG as of 2026-08-25 | 0.75 | -0.78 | RARE lower |
| Net margin as of 2026-08-25 | +16.8% | -81.7% | ALNY higher |
| Gross margin as of 2026-08-25 | +79.7% | +83.1% | RARE higher |
| Operating margin as of 2026-08-25 | +19.9% | -73.7% | ALNY higher |
| ROE as of 2026-08-25 | +93.6% | -414.2% | ALNY higher |
| ROA as of 2026-08-25 | +15.8% | -44.4% | ALNY higher |
| Debt / equity as of 2026-08-25 | 2.02 | 90.54 | ALNY lower |
| Revenue growth (YoY) as of 2026-08-25 | +95.1% | +17.5% | ALNY higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +22.8% | ALNY higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-08-25 | 0.25 | 0.28 | |
| 1-year return as of 2026-08-24 close | -48.1% | -12.5% | RARE higher |
Fundamentals: market data, as of 2026-08-25. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.